Key result
Pharmacologic inhibition of PI3Kγ with AS-605240 reduced infarct size at 4 weeks compared to vehicle and improved cardiac remodeling in mice after AMI.
Why the study?
Does pharmacologic inhibition of PI3Kγ with AS-605240 improve infarct resorption and prevent adverse cardiac remodeling in mice after experimental AMI?
RCT
randomly assigned
Does pharmacologic inhibition of PI3Kγ with AS-605240 improve infarct resorption and prevent adverse cardiac remodeling in mice after experimental AMI?
Pharmacologic inhibition of PI3Kγ with AS-605240 in a mouse model of AMI reduces infarct size and prevents adverse cardiac remodeling.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for PI3Kγ inhibition after AMI; human trials needed before clinical translation.
BACKGROUND: Phosphoinositide 3-kinase gamma is upregulated in the heart during acute myocardial infarction (AMI) potentially contributing to the development and maintenance of heart failure. METHODS: CD-1 male mice were randomly assigned to pharmacologic inhibition of phosphoinositide 3-kinase gamma using AS-605240 (10 mg/kg/day intraperitoneally) or vehicle (NaCl 0.9% + DMSO 25% solution) for 14 days after experimental AMI induced by surgical coronary artery ligation. Echocardiography was performed at baseline and 1, 7, 14, and 28 days after surgery to measure left ventricular dimensions and function. Infarct size was also measured at weekly intervals to evaluate for infarct resorption. RESULTS: When compared with vehicle-treated mice over the 4-week period, animals treated with AS-605240 showed a smaller increase in left ventricular cavitary dimensions, a smaller decrease in left ventricular systolic function (P < 0.05), and a significant increase in posterior wall diastolic and systolic thickness reflective of compensatory hypertrophy (P < 0.05). Initial infarct size (measured at 24 hours) was not different comparing AS-605240 (29% ± 4%) and vehicle-treated mice (31% ± 1%, P = nonsignificant). At 4 weeks after AMI, infarct size was significantly smaller in the AS-605240-treated mice (14% ± 2%) compared with vehicle-treated mice (28% ± 3%, P < 0.001), reflecting greater infarct resorption. CONCLUSIONS: Phosphoinositide 3-kinase gamma inhibition with AS-605240 after AMI leads to enhanced infarct resorption, greater compensatory hypertrophy of the nonischemic myocardium, and more favorable cardiac remodeling and function.
No takes yet. Share an insight, caveat, or question.
Seropián et al. (2010) conducted an RCT in Acute myocardial infarction. AS-605240 vs. Vehicle (NaCl 0.9% + DMSO 25% solution) was evaluated on Infarct size at 4 weeks after AMI (p=<0.001). Pharmacologic inhibition of PI3Kγ with AS-605240 reduced infarct size at 4 weeks compared to vehicle and improved cardiac remodeling in mice after AMI.
Synapse has enriched 10 related papers. Consider them for comparative context: